Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 903

Results For "C"

9540 News Found

Dr. Reddy’s seeks approval to continue Phase 3 trial
News | January 13, 2021

Dr. Reddy’s seeks approval to continue Phase 3 trial

The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.


LASA receives WHO nod for its Ratnagiri unit
Policy | January 13, 2021

LASA receives WHO nod for its Ratnagiri unit

Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.


States need to capture vaccination data: R. S. Sharma
Policy | January 11, 2021

States need to capture vaccination data: R. S. Sharma

Their feedback and the consequent changes in software/protocols based on those inputs were deliberated upon.


Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn
News | January 08, 2021

Biocon Biologics receives US $75 mn from ADQ; Valuation reaches US $4.17 Bn

Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.


Aditya Puri joins as director of Stelis Biopharma
People | January 08, 2021

Aditya Puri joins as director of Stelis Biopharma

Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.


Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients
Drug Approval | February 07, 2026

Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors


Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial
Clinical Trials | February 04, 2026

Pfizer’s monthly obesity drug shows breakthrough weight loss in Phase 2b trial

The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated


Zydus Wellness net sales up by 113.7% in Q3 FY26
News | February 04, 2026

Zydus Wellness net sales up by 113.7% in Q3 FY26

Glucon-D maintained its leadership position with a 59% MAT market share


Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
News | January 30, 2026

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year


Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
News | January 30, 2026

Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%

The base Gland business posted ?11,790 million in revenue, up 16% YoY